2023
Sex-specific analysis of intravascular lithotripsy for peripheral artery disease from the Disrupt PAD III observational study
Nagpal S, Altin S, McGinigle K, Mangalmurti S, Adams G, Shammas N, Mehrle A, Soukas P, Bertolet B, Lansky A. Sex-specific analysis of intravascular lithotripsy for peripheral artery disease from the Disrupt PAD III observational study. Journal Of Vascular Surgery 2023, 79: 358-365. PMID: 37925039, DOI: 10.1016/j.jvs.2023.10.058.Peer-Reviewed Original ResearchPeripheral artery diseaseLower extremity peripheral artery diseaseIntravascular lithotripsyResidual stenosisArtery diseaseAcute safetyObservational studyLow ankle-brachial indexUse of IVLChronic limb-threatening ischemiaFinal residual stenosisPeripheral intravascular lithotripsySevere lesion calcificationAnkle-brachial indexLimb-threatening ischemiaReference vessel sizeAbrupt vessel closureHigh complication rateRates of diabetesFisher's exact testSex-specific analysesAngiographic complicationsAtherectomy useIVL treatmentEfficacy outcomes
2011
Impact of Lesion Length and Vessel Size on Clinical Outcomes After Percutaneous Coronary Intervention With Everolimus- Versus Paclitaxel-Eluting Stents Pooled Analysis From the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials
Claessen BE, Smits PC, Kereiakes DJ, Parise H, Fahy M, Kedhi E, Serruys PW, Lansky AJ, Cristea E, Sudhir K, Sood P, Simonton CA, Stone GW. Impact of Lesion Length and Vessel Size on Clinical Outcomes After Percutaneous Coronary Intervention With Everolimus- Versus Paclitaxel-Eluting Stents Pooled Analysis From the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials. JACC Cardiovascular Interventions 2011, 4: 1209-1215. PMID: 22115661, DOI: 10.1016/j.jcin.2011.07.016.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryCardiovascular AgentsChi-Square DistributionCoronary AngiographyCoronary StenosisDrug-Eluting StentsEverolimusFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMyocardial InfarctionPaclitaxelPredictive Value of TestsProportional Hazards ModelsProsthesis DesignRandomized Controlled Trials as TopicRisk AssessmentRisk FactorsSeverity of Illness IndexSirolimusThrombosisTime FactorsTreatment OutcomeConceptsMajor adverse cardiac eventsPaclitaxel-eluting stentsReference vessel diameterEverolimus-eluting stentsPercutaneous coronary interventionLong lesionsGroup BLesion lengthMACE rateCoronary interventionSmall vesselsGroup AStent typeShort lesionsAdverse cardiac eventsHigh-risk patientsPatient-level dataLarge vesselsLower ratesCOMPARE trialLesion revascularizationEfficacy outcomesAdverse eventsCardiac eventsIndependent predictors
2010
Comparison of Everolimus-Eluting and Paclitaxel-Eluting Coronary Stents in Patients Undergoing Multilesion and Multivessel Intervention The SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) and SPIRIT IV (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) Randomized Trials
Kereiakes DJ, Sudhir K, Hermiller JB, Gordon PC, Ferguson J, Yaqub M, Sood P, Su X, Yakubov S, Lansky AJ, Stone GW. Comparison of Everolimus-Eluting and Paclitaxel-Eluting Coronary Stents in Patients Undergoing Multilesion and Multivessel Intervention The SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) and SPIRIT IV (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) Randomized Trials. JACC Cardiovascular Interventions 2010, 3: 1229-1239. PMID: 21232716, DOI: 10.1016/j.jcin.2010.09.014.Peer-Reviewed Original ResearchMeSH KeywordsAngioplasty, Balloon, CoronaryAntineoplastic Agents, PhytogenicCoronary Artery BypassCoronary Artery DiseaseDrug-Eluting StentsEverolimusFemaleHumansImmunosuppressive AgentsKaplan-Meier EstimateMaleMiddle AgedPaclitaxelRandomized Controlled Trials as TopicSirolimusTime FactorsUnited StatesConceptsPaclitaxel-eluting stentsIschemia-driven target lesion revascularizationTarget vessel myocardial infarctionSPIRIT IV trialTarget lesion revascularizationVessel myocardial infarctionLesion revascularizationMultivessel diseaseMultivessel interventionAbsolute benefitMyocardial infarctionOptimal revascularization strategySingle-vessel interventionDe novo lesionsReference vessel diameterEverolimus-ElutingMultilesion interventionEfficacy outcomesNovo lesionsRevascularization strategyCoronary diseaseClinical outcomesCoronary arteryClinical safetySingle lesion